Big Moving Stock keep track of the biggest moving stocks in the market.
The Hot Industries
Aerospace/Defense Products & Services 2
The Hot Sectors
Industrial Goods 4
CELG Celgene Corporation
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The companys commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The companys pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohns and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog21 Aug 2014, 4:12 pmBristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments21 Aug 2014, 2:20 pmBristol-Myers (BMY) inked an oncology deal with Celgene (CELG).
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus20 Aug 2014, 8:08 amLast week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog19 Aug 2014, 12:13 pmBiogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
3 Reasons Celgene Corporation's Stock Could Rise18 Aug 2014, 12:11 pm3 Reasons Celgene Corporation's Stock Could Rise
Critical Alerts For Advanced Micro Devices, Celgene, Weibo, SunPower, and Time Warner Released By InvestorsObserver5 Aug 2014, 8:23 amCHICAGO, Aug. 5, 2014 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, CELG, WB, SPWR, and TWX. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note:...
Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales25 Jul 2014, 12:45 pmCelgene (CELG) reported higher than expected earnings on strong revenues.
Will This Price Target Increase Help Celgene (CELG) Stock Today?25 Jul 2014, 7:31 amNEW YORK (TheStreet) -- Credit Suisse increased its price target on Celgene to $113, increased its estimates through 2016 and set an "outperform" rating. The firm cited the company's new guidance as the reason for the move. The stock was down 0.39% to $85.85 in pre-market trading on Friday. Must Read: Warren Buffett's 25 Favorite Stocks STOCKS TO BUY: TheStreet Quant Ratings has identified a ...
Celgene (CELG) Stock Falls After Mixed Second-Quarter Earnings24 Jul 2014, 7:43 am(Update 9:45 a.m.): Updated with conference call information and stock price. NEW YORK (TheStreet) -- Celgene fell 2.01% to $87.33 in early morning trading on Thursday after the biotechnology company reported mixed second-quarter results. Celgene reported a year-over-year increase in net profit to $597.8 million, or 72 cents a share, from $478.1 million, or 56 cents a share. Profit excluding ...
Jim Cramer's Top Stock Picks: PEP CELG GILD REGN BIIB CMG24 Jul 2014, 4:13 amSearch Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Wednesday's Mad Money on CNBC: PEP data by YCharts Pepsico : Looking for a winner in the consumer packaged-goods space? Cramer said Pepsico remains a favorite in the sector. \CELG data by YCharts Celgene ...